Have we overlooked the role of mifepristone for the medical management of tubal ectopic pregnancy?
RU148
ectopic pregnancy
fallopian tube
methotrexate
mifepristone
Journal
Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
12
01
2023
revised:
12
05
2023
medline:
2
8
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
Ectopic pregnancy is a risk of both spontaneous and assisted reproduction pregnancies. The majority of ectopic pregnancies abnormally implant within a fallopian tube (extrauterine pregnancies). In haemodynamically stable women, medical or expectant treatment can be offered. Currently accepted medical treatment is using a drug called methotrexate. However, methotrexate has potential adverse effects, and a significant proportion of women will still require emergency surgery (up to 30%) to remove the ectopic pregnancy. Mifepristone (RU-486) has anti-progesterone effects and has a role in managing intrauterine pregnancy loss and termination of pregnancy. On reviewing the literature and given progesterone's pivotal role in sustaining pregnancy, we propose that we may have overlooked the role of mifepristone in the medical management of tubal ectopic pregnancy in haemodynamically stable women.
Identifiants
pubmed: 37295950
pii: 7193344
doi: 10.1093/humrep/dead116
pmc: PMC10391312
doi:
Substances chimiques
Mifepristone
320T6RNW1F
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1445-1448Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
Références
Cochrane Database Syst Rev. 2022 May 24;5:CD002855
pubmed: 35608608
Hum Reprod. 2013 Jan;28(1):60-7
pubmed: 23081873
Contraception. 2003 Dec;68(6):421-6
pubmed: 14698071
Lancet. 2023 Feb 25;401(10377):655-663
pubmed: 36738759
Gynecol Obstet Invest. 1990;30(4):224-7
pubmed: 2289703
J Gynecol Obstet Hum Reprod. 2022 Apr;51(4):102330
pubmed: 35231648
Cochrane Database Syst Rev. 2019 Jun 17;6:CD002253
pubmed: 31206170
BMJ. 2011 Jun 10;342:d3397
pubmed: 21665933
Am J Obstet Gynecol. 2009 Mar;200(3):338.e1-4
pubmed: 19254596
Hum Reprod. 2020 Sep 1;35(9):2097-2106
pubmed: 32876325
Eur J Obstet Gynecol Reprod Biol. 2002 Mar 10;101(2):113-20
pubmed: 11858883
Obstet Gynecol Int. 2014;2014:423708
pubmed: 25580127
Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):640-3
pubmed: 9757964
Trials. 2018 Nov 20;19(1):643
pubmed: 30458863
Reprod Toxicol. 2009 Jan;27(1):85-7
pubmed: 19103279
Ultrasound Obstet Gynecol. 2006 Jan;27(1):91-100
pubmed: 16374758
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005216
pubmed: 21249669
Therapie. 2016 Sep;71(4):389-94
pubmed: 27203166
Endocrine. 2001 Jul;15(2):147-55
pubmed: 11720240
J Reprod Immunol. 2013 Mar;97(1):43-50
pubmed: 23432871
Hum Reprod. 2003 Sep;18(9):1802-8
pubmed: 12923131
Hum Reprod. 2020 Sep 1;35(9):e2
pubmed: 32898864
Reprod Fertil. 2021 Feb 26;2(1):C1-C7
pubmed: 35128435
BMC Pregnancy Childbirth. 2013 Feb 01;13:30
pubmed: 23369098
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000324
pubmed: 17253448
Hum Reprod. 1998 Jul;13(7):1987-90
pubmed: 9740462
BJOG. 2011 Mar;118 Suppl 1:1-203
pubmed: 21356004
Obstet Gynecol. 1994 Jun;83(6):1033-7
pubmed: 7514779